Alla.Si
Alla Therapeutics is a biotechnology company focused on developing and commercializing therapies for rare diseases, primarily generating revenue through product sales and research collaborations.
Business. Alla Therapeutics is a biotechnology company focused on developing and commercializing therapies for rare diseases, primarily generating revenue through product sales and research collaborations.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Alla Therapeutics is a biotechnology company focused on developing and commercializing therapies for rare diseases, primarily generating revenue through product sales and research collaborations.
Alla Therapeutics maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.73, indicating moderate leverage. The company holds $16.4 million in cash and equivalents, but this is offset by $17.8 million in long-term debt, resulting in a net cash position that is negative. The current ratio of 1.18 suggests the company has sufficient short-term assets to cover its liabilities, though not with a large margin of safety.
In terms of profitability, Alla Therapeutics reports a return on equity (ROE) of 6.25% and a return on assets (ROA) of 1.67%. These figures are below the industry median for ROE and ROA in the Healthcare Facilities & Services sector, indicating that the company is underperforming relative to its peers in terms of capital efficiency and asset utilization.
The company's revenue is concentrated in a limited number of segments and geographic regions, as disclosed in its financial filings. While the exact breakdown is not provided, the biotechnology industry is known for high concentration in a few key therapeutic areas and markets, which can expose the company to significant revenue volatility.
Looking ahead, Alla Therapeutics is projected to experience modest revenue growth in the current fiscal year, with a slight increase expected in the following year. The company's operating income and net income have shown positive trends, but the pace of growth remains constrained by the competitive landscape and regulatory environment.
The company faces several risk factors, including liquidity constraints due to its net cash position and the potential for dilution if it issues additional shares to fund operations or new product development. The risk assessment indicates a low probability of dilution in the near term, but the company may need to raise capital in the future to support its growth initiatives.
Recent filings and transcripts indicate that Alla Therapeutics is actively engaged in clinical trials and has ongoing discussions with regulatory bodies to advance its pipeline. The company has also been in talks with potential partners to expand its market reach and secure additional funding.
- Alla Therapeutics has a moderate debt load and a current ratio of 1.18, indicating a balanced but not robust liquidity position.
- The company's ROE and ROA are below industry medians, suggesting underperformance in capital efficiency and asset utilization.
- Revenue is likely concentrated in a few therapeutic areas and geographic regions, increasing exposure to market volatility.
- The company is projected to experience modest revenue growth, but faces liquidity and dilution risks.
- Recent developments include clinical trial progress and regulatory discussions, which could impact future growth and funding.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ALLA.SI Market data — financials · 2026-05-27